Interleukin-15 as an immune adjuvant to increase the efficacy of Mycobacterium bovis bacillus Calmette-Guérin vaccination

Masayuki Umemura; Hitoshi Nishimura; Kimika Saito; Toshiki Yajima; Goro Matsuzaki; Satoru Mizuno; Isamu Sugawara; Yasunobu Yoshikai

doi:10.1128/IAI.71.10.6045-6048.2003

Interleukin-15 as an immune adjuvant to increase the efficacy of Mycobacterium bovis bacillus Calmette-Guérin vaccination

Masayuki Umemura, Hitoshi Nishimura, Kimika Saito, Toshiki Yajima, Goro Matsuzaki, Satoru Mizuno, Isamu Sugawara, Yasunobu Yoshikai

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

Interleukin-15 (IL-15) transgenic mice which had been inoculated with Mycobacterium bovis bacillus Calmette-Guérin (BCG) 24 weeks previously showed resistance against airborne infection with Mycobacterium tuberculosis H37Rv accompanied by an increased CD8⁺-Tcl-cell response. IL-15 may be used as an immune adjuvant given with BCG vaccination to enhance its biologic efficacy.

Original language	English
Pages (from-to)	6045-6048
Number of pages	4
Journal	Infection and Immunity
Volume	71
Issue number	10
DOIs	https://doi.org/10.1128/IAI.71.10.6045-6048.2003
Publication status	Published - Oct 1 2003

All Science Journal Classification (ASJC) codes

Parasitology
Microbiology
Immunology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1128/IAI.71.10.6045-6048.2003

Cite this

@article{368b877f66894ed8a40198a47719ba8a,

title = "Interleukin-15 as an immune adjuvant to increase the efficacy of Mycobacterium bovis bacillus Calmette-Gu{\'e}rin vaccination",

abstract = "Interleukin-15 (IL-15) transgenic mice which had been inoculated with Mycobacterium bovis bacillus Calmette-Gu{\'e}rin (BCG) 24 weeks previously showed resistance against airborne infection with Mycobacterium tuberculosis H37Rv accompanied by an increased CD8+-Tcl-cell response. IL-15 may be used as an immune adjuvant given with BCG vaccination to enhance its biologic efficacy.",

author = "Masayuki Umemura and Hitoshi Nishimura and Kimika Saito and Toshiki Yajima and Goro Matsuzaki and Satoru Mizuno and Isamu Sugawara and Yasunobu Yoshikai",

year = "2003",

month = oct,

day = "1",

doi = "10.1128/IAI.71.10.6045-6048.2003",

language = "English",

volume = "71",

pages = "6045--6048",

journal = "Infection and Immunity",

issn = "0019-9567",

publisher = "American Society for Microbiology",

number = "10",

}

TY - JOUR

T1 - Interleukin-15 as an immune adjuvant to increase the efficacy of Mycobacterium bovis bacillus Calmette-Guérin vaccination

AU - Umemura, Masayuki

AU - Nishimura, Hitoshi

AU - Saito, Kimika

AU - Yajima, Toshiki

AU - Matsuzaki, Goro

AU - Mizuno, Satoru

AU - Sugawara, Isamu

AU - Yoshikai, Yasunobu

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Interleukin-15 (IL-15) transgenic mice which had been inoculated with Mycobacterium bovis bacillus Calmette-Guérin (BCG) 24 weeks previously showed resistance against airborne infection with Mycobacterium tuberculosis H37Rv accompanied by an increased CD8+-Tcl-cell response. IL-15 may be used as an immune adjuvant given with BCG vaccination to enhance its biologic efficacy.

AB - Interleukin-15 (IL-15) transgenic mice which had been inoculated with Mycobacterium bovis bacillus Calmette-Guérin (BCG) 24 weeks previously showed resistance against airborne infection with Mycobacterium tuberculosis H37Rv accompanied by an increased CD8+-Tcl-cell response. IL-15 may be used as an immune adjuvant given with BCG vaccination to enhance its biologic efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0141446040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141446040&partnerID=8YFLogxK

U2 - 10.1128/IAI.71.10.6045-6048.2003

DO - 10.1128/IAI.71.10.6045-6048.2003

M3 - Article

C2 - 14500526

AN - SCOPUS:0141446040

SN - 0019-9567

VL - 71

SP - 6045

EP - 6048

JO - Infection and Immunity

JF - Infection and Immunity

IS - 10

ER -

Interleukin-15 as an immune adjuvant to increase the efficacy of Mycobacterium bovis bacillus Calmette-Guérin vaccination

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this